1. Home
  2. ICFI vs ZYME Comparison

ICFI vs ZYME Comparison

Compare ICFI & ZYME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo ICF International Inc.

ICFI

ICF International Inc.

HOLD

Current Price

$70.31

Market Cap

1.8B

ML Signal

HOLD

Logo Zymeworks Inc.

ZYME

Zymeworks Inc.

HOLD

Current Price

$27.96

Market Cap

1.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ICFI
ZYME
Founded
1969
2003
Country
United States
United States
Employees
N/A
N/A
Industry
Professional Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.8B
1.9B
IPO Year
2006
2022

Fundamental Metrics

Financial Performance
Metric
ICFI
ZYME
Price
$70.31
$27.96
Analyst Decision
Buy
Strong Buy
Analyst Count
4
11
Target Price
$99.25
$38.90
AVG Volume (30 Days)
270.9K
518.1K
Earning Date
05-07-2026
05-07-2026
Dividend Yield
0.77%
N/A
EPS Growth
N/A
33.33
EPS
4.95
N/A
Revenue
$1,229,162,000.00
$105,965,000.00
Revenue This Year
$4.12
$180.13
Revenue Next Year
$5.33
N/A
P/E Ratio
$14.72
N/A
Revenue Growth
3.72
38.87
52 Week Low
$64.34
$10.89
52 Week High
$101.71
$28.49

Technical Indicators

Market Signals
Indicator
ICFI
ZYME
Relative Strength Index (RSI) 50.05 65.32
Support Level $64.34 $22.28
Resistance Level $83.85 $28.49
Average True Range (ATR) 2.28 1.00
MACD 1.04 0.18
Stochastic Oscillator 58.47 98.12

Price Performance

Historical Comparison
ICFI
ZYME

About ICFI ICF International Inc.

ICF International Inc provides professional services and technology-based solutions to government and commercial clients, including management, marketing, technology, and policy consulting and implementation services. Its services support clients that operate in four key markets that include Energy, Environment, Infrastructure and Disaster Recovery; Health and Social Programs and Security and Other Civilian & Commercial. The Company's majority clients are United States federal government departments and agencies. It operates in a single segment, which is providing professional services.

About ZYME Zymeworks Inc.

Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. It is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.

Share on Social Networks: